Pancreatic Cancer Research

Clinical trialNANot yet recruiting

Endoscopic Ultrasound Guided Versus Percutaneous Celiac Plexus Block in Patients With Intractable Upper Abdominal Pain

Outcome
Ongoing
Phase
NA
Status
Not yet recruiting
Study type
Interventional
Start
1 December 2026
Expected end
30 June 2029
Enrollment
100 participants
Sites
1
Primary outcomes
Change in Pain Intensity from Baseline as Assessed by the Numerical Rating Scale (NRS); Change in Pain Intensity from Baseline as Assessed by the Visual Analog Scale (VAS); Incidence of Procedure-Related Adverse Events
Sponsor
Other
Results posted
No
Last update
8 October 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Upper abdominal pain is a common and often debilitating symptom in patients with pancreatic cancer and chronic pancreatitis, and is frequently under-treated by standard opioid therapy despite dose escalation and associated side effects \[1\]. In chronic pancreatitis, abdominal pain is present in the great majority of patients and is often the dominant factor driving impaired quality of life, with celiac plexus block considered an interventional option for temporary relief \[2\]. Pain arising from both malignant and benign upper abdominal pathology is transmitted through the celiac plexus, an autonomic plexus located in the retroperitoneum at the root of the celiac trunk, making it a rational target for pain-relieving intervention in either disease process \[3\]. Two image-guided approaches have been developed to interrupt this pathway: the percutaneous route, performed under fluoroscopic or CT guidance \[5\], and the endoscopic ultrasound-guided route, performed transgastrically at the time of upper endoscopy, which allows direct visualization of the celiac plexus and may reduce the risk of injury to adjacent structures compared with the percutaneous approach \[3,9\]. Neurolytic celiac plexus block has been shown to improve pain relief in patients with unresectable pancreatic cancer \[6\], while EUS-guided celiac plexus block has similarly demonstrated efficacy in relieving pain associated with chronic pancreatitis \[7\]. Direct comparisons between the two approaches, however, remain limited: existing trials and meta-analyses in both chronic pancreatitis \[2,8\] and pancreatic cancer \[4,9\] show inconsistent superiority of one technique over the other, and the choice between them in practice has historically relied more on institutional expertise than on robust head-to-head evidence

Detailed description public domain (ClinicalTrials.gov)

Primary objective To compare the efficacy and safety of endoscopic ultrasound (EUS)-guided versus percutaneous (ultrasound-guided) celiac plexus block in controlling pain in patients with upper gastrointestinal malignancies (pancreatic cancer and hepatocellular carcinoma) and chronic pancreatitis. Secondary Objectives * To compare the degree and duration of pain relief achieved by EUS-guided versus percutaneous celiac plexus block, assessed by a validated pain scale, over a 6-month follow-up period. * To compare the impact of each technique on health-related quality of life, using the EORTC QLQ-C30 (all patients) with the PAN26 module (pancreatic cancer patients only).